Colin Newbould, the Wasdell Group, discusses upcoming deadlines and what companies should be thinking about as the scope and requirements of track and trace legislation continue to change.
As the deadlines for the US Drug Supply Chain Security Act (DSCSA) and the Falsified Medicines Directive (FMD) near, pharma businesses should be prioritising the validation of their solutions. Here, Lauren Catalano, Sharp Services, offers guidance
Rapid growth from $1.64 billion in 2017 to $6.07 billion in 2024 is expected in the global orphan and rare dermatology premium products market, according to business intelligence provider, GBI Research.
After receiving approval for two HIV drugs, Delstrigo and Pifeltro, Merck should be expecting strong sales but probably unlikely to be at blockbuster levels, according to senior pharma analyst at GlobalData.
In this online exclusive, Rina Nir, managing director of RadBee, looks at why Agile and DevOps are the ultimate cure for pharma companies’ ailing computer systems validation process.
In this article with EPM, Dexter Tjoa, director of Corporate Strategy, discusses why outsourcing is fast becoming the most logical choice for companies who have delayed developing appropriate solutions and what benefits an experienced CPO can bring
Paolo Landriani, technical department director at SEA Vision, discusses the importance of the right equipment and software in this approach and how it can save space, improve quality and ultimately save manufacturers time and money.
Transparency Market Research has predicted that the global pharmaceutical robots market is set to witness high adoption of regional expansion, new product development and merger & acquisition as key business strategies, bagging $250.46m by 2026
A stark warning that ‘innovation is being hindered by regulators’ has been given by the president of EPCOT International, Girish Malhotra, in the first part of CPhI Worldwide’s sixth annual report.
In this interview, we at EPM magazine speak with Staffan Widengren, director of corporate projects at Recipharm on the difficulties CDMOs are facing leading up to the European Falsified Medicines Directive (EU FMD) deadline in February 2019.
